Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 24, 2022, Cyclo Therapeutics, Inc. (the "Company") held its 2022 Annual Meeting of Stockholders (the "Annual Meeting") to consider and vote on proposals for (i) the election of the director nominees named in the definitive proxy statement (the "Proxy Statement") for the Annual Meeting filed with the Securities and Exchange Commission on April 29, 2022 ("Proposal I"); (ii) the approval of the compensation of the Company's named executive officers ("Proposal II"); and (iii) the ratification of the appointment of WithumSmith+Brown, PC to serve as the Company's independent registered public accountants ("Proposal III"). Each of the foregoing proposals is described in more detail in the Proxy Statement. Stockholders holding an aggregate of 4,718,124 shares of common stock, representing 56.1% of the outstanding shares of the Company's common stock as of the record date, and which constituted a quorum, were present in person or represented by proxy at the Annual Meeting.

The results of the voting at the Annual Meeting are presented below.



Proposal I - The seven director nominees were all elected to the Board as
follows:

  Director               Votes For       Votes Withheld       Broker Non-Votes

  N. Scott Fine           1,945,010           54,067               2,719,047
  Markus W. Sieger        1,946,540           52,837               2,718,747
  Jeffrey L. Tate         1,945,911           53,466               2,718,747
  Randall M. Toig         1,928,495           70,882               2,718,747
  William S. Shanahan     1,582,316           414,061              2,721,747
  F. Patrick Ostronic     1,934,715           64,662               2,718,747
  C.E. Rick Strattan      1,601,208           398,169              2,718,747



Proposal II - The compensation of the Company's named executive officers was
approved as follows:

   For         Against      Abstain       Broker Non-Votes

1,727,240       225,055       47,082           2,718,747



Proposal III - The ratification of the appointment of WithumSmith+Brown, PC was
approved as follows:

   For        Against      Abstain      Broker Non-Votes

4,652,221       31,278       34,625              N/A

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses